Terminated PHASE2/PHASE3 INTERVENTIONAL 4-arm NCT00387686

A Phase 2/3 Multicenter, Controlled Trial Of rhBMP-2/CPM In Tibial Fractures

A Phase 2/3, Multicenter, Double-Blind, Randomized, Controlled Study Of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2)/Calcium Phosphate Matrix (CPM) In Closed Diaphyseal Tibial Fracture

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Conditions Fractures

Interventions rhBMP-2/CPM

Updated 12 times since 2017 Last updated: Feb 21, 2013 Started: Nov 30, 2006 Primary completion: Jul 31, 2009 Completion: Mar 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Decision was taken by Wyeth Sr. Management to early terminate the 3100N7-210 study (terminate enrollment but complete follow-up).

Other terminated trials from Wyeth is now a wholly owned subsidiary of Pfizer

See all terminations from Wyeth is now a wholly owned subsidiary of Pfizer

Listed as NCT00387686, this PHASE2/PHASE3 trial focuses on Fractures and remains terminated or withdrawn. Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, it has been updated 12 times since 2006, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

12 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2/PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Apr 2022 — Jul 2024 [monthly]

Terminated PHASE2_PHASE3
Dec 2021 — Apr 2022 [monthly]

Terminated PHASE2_PHASE3

▶ Show 7 earlier versions

Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2_PHASE3
Nov 2020 — Jan 2021 [monthly]

Terminated PHASE2_PHASE3
Jun 2018 — Nov 2020 [monthly]

Terminated PHASE2_PHASE3
May 2018 — Jun 2018 [monthly]

Terminated PHASE2_PHASE3
Aug 2017 — May 2018 [monthly]

Terminated PHASE2_PHASE3
Feb 2017 — Aug 2017 [monthly]

Terminated PHASE2_PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2_PHASE3

First recorded

Nov 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Wyeth is now a wholly owned subsidiary of Pfizer

Data source: Wyeth is now a wholly owned subsidiary of Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Ahmedabad, India , Ajax, Canada , Alcalá, Spain , Alcalá de Henares, Spain , Angers, France , Aurora, United States , Baltimore, United States , Belgrade, Serbia , Berlin, Germany and 53 more locations